David Taussig, MRCP, FRCPath, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses preliminary results from an ongoing Phase I/IIa study which is evaluating the safety and tolerability of EP0042, a dual FLT3 and aurora kinase inhibitor, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) (NCT04581512). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Video provided by Video Journal of Hematology & HemOnc
